Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Immunotherapy is revolutionizing the treatment of non–small cell lung cancer (NSCLC). Immune checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies, are being introduced to routine clinical practice. This review summarizes clinical trials of nivolumab, pembrolizumab, and atezolizumab in patients with NSCLC. These agents have efficacy against NSCLC and a unique toxicity profile. The role of PD-L1 as a predictive biomarker is still unclear, partially because of the nuances of PD-L1 testing. These novel therapies also challenge our existing methodologies of radiologic assessment and efficacy analysis. This new era of immunotherapy has ushered in as much hope for patients as questions from physicians that need to be answered to clarify the optimal use of these agents.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalBioDrugs
DOIs
StateAccepted/In press - Jul 13 2016

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology

Fingerprint Dive into the research topics of 'Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab'. Together they form a unique fingerprint.

Cite this